NCT06040541phase 1recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Revolution Medicines, Inc.

ClinicalTrials.gov

604

Enrollment · estimated

Countries · 17 sites

2026-12

Primary completion

3 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Biomarker requirement language

Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
55/100
Opportunity
New phase 1 trial NCT06040541 posted by Revolution Medicines, Inc.: "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors".
ClinicalTrials.gov record updated 97 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
* ECOG performance status 0 or 1
* Adequate organ function

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Known or suspected leptomeningeal or active brain metastases or spinal cord compression
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

Other inclusion/exclusion criteria may apply.